The Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 pipeline drugs market research report outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Genito Urinary System, and Genetic Disorders which include the indications Epilepsy, Seizures, Primary Hyperoxaluria, Primary Hyperoxaluria Type I, and Fragile X Syndrome. It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 2, and 2 respectively.
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 overview
Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded by the GABRA3 gene. GABRA3 are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control.
For a complete picture of Gamma-Aminobutyric Acid Receptor Subunit Alpha 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
